The discovery and development of Viagra® (sildenafil citrate)

Name: The discovery and development of Viagra® (sildenafil citrate)
Creator: Ian H. Osterloh
Keywords: 3. Good health

descriptionPublicationkeyboard_double_arrow_right Part of book or chapter of book , Other literature type 01 Jan 2004 English Publisher:Birkhäuser Basel

Authors: Ian H. Osterloh;

doi: 10.1007/978-3-0348-7945-3_1

The discovery and development of Viagra® (sildenafil citrate)

- Summary
- Metrics

Abstract

Sildenafil citrate (UK-92,480, Viagra®) is a selective inhibitor of phosphodiesterase type 5 (PDE5) and acts on the nitric oxide (NO)/cyclic guanosine monophosphate (cGMP) pathway [1, 2]. UK-92,480 was first synthesised in the Sandwich laboratories of Pfizer Ltd, UK in 1989, and resulted from a discovery programme aimed at developing a selective inhibitor of PDE5. The origins of the project that eventually led to the discovery and development of Viagra date from around the mid 1980s. At this time, scientists working at the Pfizer European Research Centre were interested in potential new approaches to the treatment of several cardiovascular diseases.

Related Organizations

Pfizer (United States)
United States

Impact byBIP!

	citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	14
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 10%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average